Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Actuate Therapeutics IncNASDAQ: ACTU
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$160.23M, compared with -$138.7M a year earlier.
Context
- Retained earnings amounted to 1798.1% of total assets at the end of Q1 FY2026, down 1295.7 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -15.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (154.61M) USD
- Year-over-year change
- -16.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (154.61M) | -16.8% |
| FY2024 | 2024-12-31 | (132.38M) | -26.0% |
| FY2023 | 2023-12-31 | (105.09M) | -30.8% |
| FY2022 | 2022-12-31 | (80.35M) | — |
Retained Earnings vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -15.5% is the 4th highest of 9, against a peer median of -18.5%.
- Retained earnings amounts to 1798.1% of total assets for ACTU, versus a peer median of 392.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ACTUActuate Therapeutics Inc | Mar 2026 | -$160.23M USD | -15.5% | — | 1798.1% |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$245.5M USD | -19.6% | — | 1082.0% |
| Mar 2026 | -CHF 323.66M CHF | -24.1% | — | 370.3% | |
| Mar 2026 | -$378.88M USD | -25.6% | — | 242.4% | |
| Mar 2026 | -$458.27M USD | +3.2% | — | 776.5% | |
| Mar 2026 | -$676.14M USD | -17.3% | — | 181.7% | |
| Mar 2026 | -$992.32M USD | -5.0% | — | 843.7% | |
| Mar 2026 | -$994.99M USD | -14.4% | — | 414.7% | |
| Mar 2026 | -$1.37B USD | -180.4% | — | 270.9% | |
| Peer median (excluding ACTU) | — | -18.5% | — | 392.5% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.